Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P52742 (pT3)
 1,034 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prognostic factors were studied in 91 patients with diagnosed renal adenocarcinoma in stages pT1-4/N0-3/V0-2/M0. All patients had been treated with radical surgery, extended nephrectomy with or without cardiopulmonary by-pass and extracorporeal circulation in those cases with suprahepatic tumoral thrombosis. The tumoral features which have a significant incidence on the patient's survival rate are the degree of cellular anaplasia, GI 72% vs GII 42% vs GIII 22% (p less than 0.0001); pathological stage, pT1-2 86% vs pT3 30% (p = 0.0000), perirenal fat invasion, pT1-2 86% vs pT3a 61% (p = 0.01); renal vein or cava vein invasion, V0 72% vs V1-2 30% (p less than 0.01) and gangliar affection. N0 69% vs N1-3 11% (p = 0.0000). Development of systemic disease is significantly high in pT3 stages (p = 0.0001), mainly in pT3a (p = 0.01), N1-3 (p less than 0.05) and/or V1-2 (p = 0.01). There is premature development of metastasis conditioning death before the second year o study in 90% of patients. In our opinion, patients with renal adenocarcinoma in stages pT3a/N0/M0, pT3b/N0/M0 and pT2-4/N1-3/M0 present a high potential risk of developing metastatic disease following radical surgery. These patients, as well as those with high degree tumours and presumably minimum residual disease, are candidates for supplementary therapy with lymphokine immunotherapy (rIL-2,FNT, alpha or gamma IF, etc) with or without adoptive cellular immunotherapy (LAK or TIL) following radical surgery, and extended nephrectomy plus tumoral thrombectomy, if required, with or without cardiopulmonary bypass.
 ...
PMID:[Neoadjuvant immunotherapy in non-metastatic renal adenocarcinoma]. 208 Jul 25

Eighty-two patients with stage T3 carcinoma of the prostate were treated for 3 months prior to radical retropubic prostatectomy with a luteinizing-hormone-releasing hormone analogue and an antiandrogen. Based on digital rectal examination (DRE), reduction of prostate and tumor size was noted in all cases. Ultrasound demonstrated a decrease in prostatic volume between 0 and 62.5% (median 32%). Prostate-specific antigen levels (PSA, Hybritech) decreased substantially (mean PSA of 29.5 ng/ml before to a mean PSA of 1.3 ng/ml after hormonal treatment). Pathologically, only 15 patients (18.3%) had organ-confined disease (stage pT2), 44 (53.7%) had stage pT3 tumors and 22 (26.8%) had positive lymph nodes. In 1 surgical specimen (1.2%), no residual tumor was identified. In 5 patients with nodal metastasis and 13 patients with seminal vesicle invasion, PSA levels after pretreatment were below 0.5 ng/ml. Compared to the preoperative needle biopsy, a decrease in the histological grade was found in only 7 tumors, while an increase was noted in 26. DRE, ultrasound and PSA suggest a downstaging of stage T3 prostate cancer after 3 months of maximum androgen deprivation. This cannot be confirmed pathologically. Prospective studies with this treatment regimen should concentrate on a possible benefit concerning local and distant cancer control and survival.
 ...
PMID:Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. 853 74

In the last few years percutaneous cryoablation surgery of the prostate has been re-introduced as an alternative means to treat prostatic carcinoma. Advantages of the technique include local effectiveness in eradicating tumors, minimal morbidity rate and lower costs when compared to radical surgery. We report a study documenting the histopathological changes seen in 317 biopsy specimens obtained from 30 patients (age range 59-83 years, median 73 years) treated with cryosurgical ablation for prostate cancer. Pre- and postoperatory assessment was inclusive of plain clinical, laboratory and instrumental data (digital rectal examination, transrectal ultrasound scan, serum prostatic specific antigen concentration) and systematic biopsies obtained from conventional and modified prostate sextants. Fifteen patients had tumors extending through the prostate capsule (pT3 and pT4). Six patients had stage PT1 tumors and 9 had stage pT2. Tissues were sampled at 3, 6 and between 12-18 months postoperatively. The histologic findings, in decreasing order of frequency, were: full core fibrosis, necrosis, granulation tissue, basal cell hyperplasia, cell swelling, hemosiderin deposits, chronic inflammation, thick nerves and prostatic hyperplasia. Necrosis was of the coagulative type, sometimes associated with nuclear debris, and seen at relatively short interval from cryotherapy. Fibrosis with hyaline qualities was seen especially at 12-18 month interval. The presence of necrosis, as well as granulation tissue, hemosiderin deposits and cell swelling, strongly correlate to intervals from cryosurgical ablation. Residual tumor tissue was focal (0.5-1 mm) and recognizable in 9 cores from 4 patients (13.3%) sampled especially from the prostatic apex. Incipient tumor necrosis was seen in 11 cores, without particular distribution. These findings indicate that cryosurgery results in distinctive changes in both tumoral and non-tumoral prostate tissue. Knowledge of the histopathologic patterns is important since it provides the clinicians with information on treatment efficacy or failure, and could assist in the selection of larger groups of patients eligible to cryosurgical ablation.
 ...
PMID:Histopathology of the frozen prostate. The microscopic bases of prostatic carcinoma cryoablation. 885 46

Some 50 total mesorectal excision specimens were examined following rectal excision for cancer. Circumferential margin involvement was rare, but mesorectal tumour deposits were present in 17 of 44 patients with pT3 tumours, and 23 of 44 had mesorectal nodal involvement. No patient with a pT2 tumour had mesorectal involvement. Failure to excise the mesorectum completely has the potential to leave gross or microscopic residual disease that may in theory predispose to local failure. Total mesorectal excision is necessary to avoid incomplete pathological evaluation of the mesorectum and understaging of rectal cancer.
 ...
PMID:Pathological evidence in support of total mesorectal excision in the management of rectal cancer. 886 20

There is no debate that both the earlier diagnosis and the treatment of men with cancer of the prostate (CaP) are having an impact on patients with this disease. In many practices there are fewer and fewer patients presenting with the classic diagnosis of 'advanced disease', i.e., stage M (D2). Only a few years ago, a large percentage of men with CaP had bony metastases when they presented to a physician. Hormonal ablation was the optimal treatment, and the only question was whether bilateral orchiectomy or medical castration should be used. The median time to progression with either type of monotherapy was 12-18 months, and the median time to survival was 24-36 months. Unfortunately, in many parts of the world, this scenario is still the norm. In the United States, Europe, and an increasing number of other countries, improved methods of detection with transrectal ultrasound and prostate-specific antigen (PSA) have resulted in a dramatic shift in the stage of disease at diagnosis. It is safe to say that in these countries the majority of prostate cancers are now being clinically diagnosed while still localized, and many organ-confined tumors are being definitively treated and cured. Nevertheless, many of these patients will be understaged at the time of diagnosis and will show progression following definitive therapy. In most surgical series approximately one half of patients will be found on pathologic examination to have pT3 disease. The use of PSA in the diagnosis of CaP has been mentioned, and it is being used extensively to monitor recurrent/residual disease. Hormonal therapy is being employed earlier in numerous clinical situations, and its use is no longer reserved solely for patients with metastatic disease. In this context combined androgen blockade has become the gold standard of treatment in neoadjuvant situations as well as for advanced CaP. Newer advances, including 3-month depot formulations of luteinizing hormone-releasing hormone analogues, the reversibility of medical castration, the preference of most patients to have medical castration, and the approval of other antiandrogens in the United States, all have further strengthened the use of combined androgen blockade. Hormonal therapy in adjuvant settings, when there is a high likelihood of disease recurrence, is also being used in many clinical situations. In addition, there appears to be a role for certain types of hormonal therapy in chemoprevention.
 ...
PMID:Combined androgen blockade: the gold standard for metastatic prostate cancer. 926 89

The objective was to evaluate the results of a combination of surgery and postoperative radiotherapy in patients with uterine sarcoma, to describe the patterns of relapse and to define prognostic factors. From 1980 to 1993, 29 patients (median age: 56 years) presenting with uterine sarcoma have been treated with surgery and postoperative irradiation. The histology was: leiomyosarcoma: 11; carcinosarcoma: 12; stromal sarcoma: 6. The distribution by stage was: pT1: 18; pT2: 5; pT3: 3; pT4: 3; pNO: 27; pN1: 2. Gross residual disease was present in 4 patients. External beam irradiation was performed in all the cases and brachytherapy in 19. Chemotherapy was given in 3 patients. The overall survival rate was 66% at 2 years and 57% at 5 years with a disease free survival of 54% at 2 years and 50% at 5 years. Seven patients relapsed locally and 8 developed metastases. One patient died of ileitis. In a multivariate analysis, the disease free survival was strongly influenced by the menopausal status. The survival in this study is higher than that described in series of patients treated with surgery alone. This study confirms the worse prognosis of uterine sarcoma in postmenopausal women.
 ...
PMID:[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy]. 929 66

The close cooperation of the surgeon and the pathologist in clinical practice and research of colorectal cancer was far established. The histopa-histopathological report has to include all important information in relation to tumour classification, prognostic factors and surgical procedure. This is the starting point for further treatment, estimation of prognosis and treatment results, indicator of oncological quality of surgical procedure and the most important contribution to increasing knowledge of clinical pathobiology related to colorectal cancer. To reach these goals the pathologist should follow some of up-dated histopathological protocols for the examination of specimen removed from patients with colorectal carcinoma. Most of the proposals and international standards are presented in detail. The applying of three main classifications for colorectal carcinoma is mandatory, i.e. histopathological classification, the disease stage (pathoanatomic extension) classification and residual disease classification. It seems that the first and most important step is R (residual disease) classification, serving as the most reliable determinant in further treatment, prognosis and in assessment of surgical treatment. The focus of surgery on R0 category subgroup of patients is presented in relation to the disease stage as second proven prognostic factor, strongly influencing the prognosis and adjuvant therapy options. The detection and significance of minimal residual disease, mainly occult micrometastases in examined lymph nodes are essential for more accurate staging of the disease. Our own data from pilot study confirmed the significant stage migration (Will Rogers phenomenon of "up-grading"). Using combination of serial sectioning and immunohistochemical reactivity of anti-cytokeratin antibody to scattered micrometastatic foci in lymph nodes and perirectal fat, we have shown the presence of minimal residual disease in 23.53% of R0 pT3 pN0 primary classified cases. Correlation to other probable and possible histological independent prognostic factors is discussed, as well as the most significant molecular prognostic markers.
 ...
PMID:Postoperative pathological examination of colorectal cancer. 1143 46

The aim of the present study was to clarify the therapeutic effect of thoracoscopic esophagectomy with radical lymph node dissection based on the recurrence pattern, and identify the risk factors for relapse-free survival in patients with esophageal cancer. The recurrence patterns in 140 patients who underwent complete thoracoscopic radical esophagectomy between January 2003 and December 2012 were investigated. The risk factors for recurrence were examined by univariate and multivariate analysis. Mediastinal recurrence in association with initial lymphatic metastasis was precisely analyzed. Esophageal cancer recurred in 49 (35.0%) of the 140 patients. The median recurrence time was 259 (45-2,560) days after the initial treatment. The patterns of initial recurrence among the 140 patients included hematological recurrence in 24 patients (17.1%), lymphatic recurrence in 26 (18.6%), pleural dissemination in 5 (3.6%), peritoneal dissemination in 2 (1.4%), and local recurrence in 4 (2.9%). Lymphatic recurrence within the mediastinal regional lymphatic stations occurred in only 8 (5.7%) of the 140 patients. Univariate analysis for relapse-free survival showed that the statistically significant variables were a tumor location in the upper third of the esophagus, stage of pT3 or pT4, presence of nodal metastasis, pStage of III or IV, presence of a residual tumor, performance of preoperative chemotherapy and performance of postoperative therapy. Multivariate analysis showed that only nodal metastasis and a positive residual tumor were statistically significant independent risk factors for relapse-free survival. Lymphatic recurrence within the mediastinum, particularly the station around the bilateral recurrent laryngeal nerves, was infrequent and independent of the initial metastatic distribution. Thoracoscopic esophagectomy with radical lymph node dissection provides favorable locoregional control. Lymphatic recurrence within the mediastinal regional nodes is infrequent and independent of the initial lymph node metastasis. A pathological residual tumor and lymph node metastasis are significant risk factors for recurrence.
 ...
PMID:Recurrence patterns and risk factors following thoracoscopic esophagectomy with radical lymph node dissection for thoracic esophageal squamous cell carcinoma. 2689 75

A 63-year-old man who presented with asymptomatic gross hematuria was referred to our hospital. Left ureteral tumor (cT3N0M0) was diagnosed and left nephroureterectomy was performed. Pathological examination revealed urothelial carcinoma and small cell carcinoma with local invasion (pT3). The patient was treated with three cycles of adjuvant chemotherapy with gemcitabine and cisplatin. Three months after the chemotherapy, cystoscopy showed an intravesical recurrence of the tumor. Transurethral resection was performed and histopathological examination revealed small cell carcinoma (pT1). We recommended a cystectomy and neoadjuvant chemotherapy with etoposide and carboplatin according to the standard care of small cell carcinoma of bladder. However, the patient refused to undergo cystectomy and desired to preserve his bladder. Therefore, after two cycles of chemotherapy with etoposide and carboplatin, transurethral resection was performed to examine the presence of the residual tumor instead of immediate cystectomy. Because of no residual tumor, another two cycles of chemotherapy were added instead of a cystectomy. There is no evidence of recurrence seven months after the chemotherapy.
...
PMID:[Intravesical Recurrence of Small Cell Carcinoma of the Ureter: A Case Report]. 2701 13

A patient in his 70's underwent a right hemi-colectomy due to an ascending colon cancer in a previous hospital. The tumor had widely infiltrated the retroperitoneal space(pT3, pN0[0/12], pPM0, pDM0, pRM1, Stage II ). He was referred to our institute 1 month after primary surgery to receive chemotherapy for his residual tumor. Abdominal computed tomography (CT)showed a 24mm tumor in his retroperitoneal space before chemotherapy. After 4 cycles of mFOLFOX6 and panitumumab, the tumor partially responded, and after 7 cycles, he achieved a complete response(CR). After an additional 10 cycles, he had maintained the CR, and chemotherapy was discontinued. Two years and 11 months after discontinuation of chemotherapy, an abdominal CT revealed a tumor that gradually grew behind the right kidney. The tumor was resected, and pathological findings showed it was recurrence of the past colon cancer. Seven months after resection of recurrent tumor, CT revealed 2 newly recurrent tumors that gradually grew in the retroperitoneal space again. Therefore, we performed resection of newly recurrent tumors along with the right kidney, Gerota's fascia, diaphragm, and lumbar quadrate muscle for R0 resection. Pathological findings revealed recurrence of the past colon cancer with extensive lymphatic invasion. The recurrent tumor had grown in a retroperitoneal space that was not covered in the primary surgical procedure. Therefore, this is considered a rare case of retroperitoneal metastasis.
 ...
PMID:[A Rare Case of Retroperitoneal Metastasis from Ascending Colon Cancer That Required Multimodal Treatment]. 2813 58


1 2 Next >>